Dr. Kamarck joined Wyeth in 2001 after more than 18 years with Bayer AG, working in the areas of Research and Development, Process Development and Operations. He last held the position of Senior Vice President of Operations at Bayer AG.
Michael D. Kowolenko, Ph.D., joins Wyeth Pharmaceuticals as Senior Vice President, Biotech Operating Unit, TO&PS. In this position, Dr. Kowolenko will lead the global Biotech Development and Manufacturing network and replaces Dr. Michael E. Kamarck, to whom he will report.
Dr. Kowolenko joins Wyeth from Biogen Idec, where he most recently served as Senior Vice President, Pharmaceutical Operations and Technology. Prior to that, Dr. Kowolenko held senior positions in large pharmaceutical and biotech companies, as well as leadership roles in quality and operations.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
